Axbio

About Axbio

Axbio operates at the intersection of semiconductors and biotechnology, focusing on making multi-omics research solutions more accessible for life sciences and clinical medicine. Established in Silicon Valley in 2016 by CEO Dr. Hui Tian and COO Igor Ivanov, the company leverages its proprietary Bio-CMOS chip technology to drive advancements in genetic analysis. Dr. Tian holds degrees from Stanford and Tsinghua University and previously led high-throughput sequencing chip development at Roche and Genia. This background in integrating chip technology with biological applications has been central to Axbio's direction. The firm has secured significant funding, including a Series A round in October 2021 and a $100 million Series B round in June 2022, with investors such as AstraZeneca-CICC, Yunfeng Capital, and 5Y Capital.

The company's core business revolves around the development and provision of fourth-generation nanopore gene sequencers, molecular diagnostic systems, biochips, and related reagents. Axbio's technology is built on a microfluidic Bio-CMOS platform that enables high-throughput, single-molecule, real-time sequencing without the need for nucleic acid amplification. This is achieved through a combination of a high-density nanopore sequencing chip, advanced electrochemical sensing, and AI-driven data analysis. The platform is designed to deliver long-read sequencing with high accuracy at a reduced cost, addressing key limitations of previous sequencing generations. Axbio's product lineup includes the AxiLona AXP-100 Nanopore Gene Sequencer and the AxiLona EL-100 Microarray Analyzer. The company also offers an automated library preparation system to streamline workflows.

Axbio serves a diverse client base, from academic research laboratories to clinical settings, including small clinics and large hospitals. Its technology has broad applications in precision medicine, such as early cancer screening, rapid pathogen detection, genetic disease analysis, and drug development. The business model includes selling instruments and consumables, as well as providing customized services like chemical synthesis and bioinformatics analysis. With R&D centers in Silicon Valley, Shenzhen, and Tianjin, and a GMP production facility in Wuxi, Axbio is positioned to support both research and clinical applications globally.